General Comments IMU, page-395

I am now in the latter years of my life, having been round the block a couple of times tolerance levels have matured. Grey hair perhaps indicative of this fact, however despite comment from those participating on this forum across the investment spectrum (novice through sophisticated) their remains one fact that cannot be denied with the management of Imugene. This being their crass failure of attention to due diligence in their mandated duty of care for the protection shareholder value. Paul Hopper’s comment as determined in his last News Letter does not relieve him nor the board of this, indeed it was a very poor attempt to place himself beyond such a responsibility. This is not being written because my holding has lost value indeed some 80% (my average buy price sub 3 cents) since the high of November last, but because the vessels Stability in terms if best practice is being called into question. It was brought to our attention previously through mention by WMHB with his noting of a discussion with Leslie and her dismissal of any alteration or deviation away from determined practices in marketing the company. Small shareholders do collectively pack a hefty punch!